Use of Fingolimod in the Management of Relapsing–Remitting Multiple Sclerosis: Experience from Latin America

Once-daily fingolimod 0.5 mg (FTY720; Gilenya(®), Novartis Pharma AG, Basel, Switzerland) is a sphingosine 1-phosphate receptor modulator that is approved for the treatment of relapsing multiple sclerosis (MS); currently, this includes approval in 13 Latin American countries. However, despite a well...

Descripción completa

Detalles Bibliográficos
Autores principales: Correale, Jorge, Flores, Jose, Bonitto, Juan Garcia, Rodríguez, Claudia Cárcamo, Oliveira, Enedina M. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4522024/
https://www.ncbi.nlm.nih.gov/pubmed/26170106
http://dx.doi.org/10.1007/s12325-015-0226-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4522024/
https://www.ncbi.nlm.nih.gov/pubmed/26170106
http://dx.doi.org/10.1007/s12325-015-0226-0

Ejemplares similares